1.Effects of metabolic surgery on islet function in Asian patients with type 2 diabetes.
Yao Quan CAO ; Hai Bo TANG ; Shai Hong ZHU ; Li Yong ZHU
Chinese Journal of Gastrointestinal Surgery 2022;25(10):892-898
Type 2 diabetes is a high-profile global public health problem, particularly in Asia. The young age of onset, low body mass index, and early appearance of pancreatic islet dysfunction are characteristics of Asian patients with T2DM. Metabolic surgery has become the standard treatment for T2DM patients and can significantly improve T2DM through a variety of mechanisms including modulation of energy homeostasis and reduction of body fat mass. Indeed, restoration of islet function also plays an integral role in the remission of T2DM. After metabolic surgery, islet function in Asian T2DM patients has improved significantly, with proven short-term and long-term effects. In addition, islet function is an important criterion and reference for patient selection prior to metabolic surgery. The mechanism of islet function improvement after metabolic surgery is not clear, but postoperative anatomical changes in the gastrointestinal tract leading to a number of hormonal changes seem to be the potential cause, including glucagon-like peptide-1, gastric inhibitory polypeptide, peptide YY, ghrelin, and cholecystokinin. The authors analyzed the current retrospective and prospective studies on the effect of metabolic surgery on the islet function of Asian T2DM patients with a low BMI and its mechanism, summarized the clinical evidence that metabolic surgery improved islet function in Asian T2DM patients with a low BMI, and discussed its underlying mechanism. It is of great significance for realizing personalized and precise treatment of metabolic surgery and further improving its clinical benefits.
Bariatric Surgery
;
Body Mass Index
;
Cholecystokinin/therapeutic use*
;
Diabetes Mellitus, Type 2/surgery*
;
Gastric Inhibitory Polypeptide/therapeutic use*
;
Ghrelin/therapeutic use*
;
Glucagon-Like Peptide 1/therapeutic use*
;
Humans
;
Peptide YY/therapeutic use*
;
Prospective Studies
;
Retrospective Studies
;
Treatment Outcome
2.Clinical observation on the combined therapy of sitagliptin with insulin for patients with brittle diabetes.
Na LUO ; Yan ZHU ; Zhenwen ZHANG ; Hui CHEN ; Yan WANG
Journal of Central South University(Medical Sciences) 2015;40(10):1089-1095
OBJECTIVE:
To observe the clinical efficacy of sitagliptin plus insulin on patients with brittle diabetes and to determine the effect of the combined therapy on glucagon secretion.
METHODS:
This randomized, double-blinded and placebo-controlled trial included 30 patients with brittle diabetes. Participants were randomly assigned (1:1) to receive the treatment of either sitagliptin plus insulin or placebo plus insulin for 12 weeks. The blood glucose, hemoglobin A1c, insulin dose, C-peptide, glucagon, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and other parameters were determined.
RESULTS:
After 12 weeks of treatment, blood glucose was controlled better by sitagliptin plus insulin (P<0.01). The patients had significantly lower glucose variability indices, lower daily insulin requirement and hemoglobin A1c in the group of sitagliptin plus insulin (P<0.01). After steamed bun test, past-meal GLP-1 levels at 30 min were higher (P<0.01) while GIP levels were lower (P<0.01), with glucagon suppression in the sitagliptin plus insulin group. No significant change was observed at any time point in placebo plus insulin group.
CONCLUSION
Sitagliptin significantly decreases blood glucose level and blood glucose fluctuation, which may contribute to the ability of sitagliptin in decreasing glucagon secretion.
Blood Glucose
;
analysis
;
C-Peptide
;
blood
;
Diabetes Mellitus, Type 1
;
drug therapy
;
Dipeptidyl-Peptidase IV Inhibitors
;
Double-Blind Method
;
Drug Therapy, Combination
;
Gastric Inhibitory Polypeptide
;
blood
;
Glucagon
;
blood
;
Glucagon-Like Peptide 1
;
blood
;
Glycated Hemoglobin A
;
analysis
;
Humans
;
Hypoglycemic Agents
;
administration & dosage
;
therapeutic use
;
Insulin
;
administration & dosage
;
therapeutic use
;
Sitagliptin Phosphate
;
administration & dosage
;
therapeutic use
3.Improving Effect of the Acute Administration of Dietary Fiber-Enriched Cereals on Blood Glucose Levels and Gut Hormone Secretion.
Eun Ky KIM ; Tae Jung OH ; Lee Kyung KIM ; Young Min CHO
Journal of Korean Medical Science 2016;31(2):222-230
Dietary fiber improves hyperglycemia in patients with type 2 diabetes through its physicochemical properties and possible modulation of gut hormone secretion, such as glucagon-like peptide 1 (GLP-1). We assessed the effect of dietary fiber-enriched cereal flakes (DC) on postprandial hyperglycemia and gut hormone secretion in patients with type 2 diabetes. Thirteen participants ate isocaloric meals based on either DC or conventional cereal flakes (CC) in a crossover design. DC or CC was provided for dinner, night snack on day 1 and breakfast on day 2, followed by a high-fat lunch. On day 2, the levels of plasma glucose, GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and insulin were measured. Compared to CC, DC intake exhibited a lower post-breakfast 2-hours glucose level (198.5±12.8 vs. 245.9±15.2 mg/dL, P<0.05) and a lower incremental peak of glucose from baseline (101.8±9.1 vs. 140.3±14.3 mg/dL, P<0.001). The incremental area under the curve (iAUC) of glucose after breakfast was lower with DC than with CC (P<0.001). However, there were no differences in the plasma insulin, glucagon, GLP-1, and GIP levels. In conclusion, acute administration of DC attenuates postprandial hyperglycemia without any significant change in the representative glucose-regulating hormones in patients with type 2 diabetes (ClinicalTrials.gov. NCT 01997281).
Adult
;
Aged
;
Area Under Curve
;
Blood Glucose/*analysis
;
Cross-Over Studies
;
Diabetes Mellitus, Type 2/complications/diagnosis/*diet therapy
;
Dietary Fiber/*therapeutic use
;
Female
;
Gastric Inhibitory Polypeptide/blood
;
Glucagon/blood
;
Glucagon-Like Peptide 1/*blood
;
Hemoglobin A, Glycosylated/analysis
;
Humans
;
Hyperglycemia/complications/diagnosis
;
Insulin/blood
;
Intestines/metabolism
;
Male
;
Middle Aged
;
ROC Curve